No black box warning on record for Foscarnet Sodium

As of the latest FDA labeling reviewed, Foscarnet Sodium (FOSCARNET SODIUM) does not carry a black box warning. Standard warnings and precautions still apply — see the full Foscarnet Sodium medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Renal Impairment THE MAJOR TOXICITY OF FOSCARNET SODIUM INJECTION IS RENAL IMPAIRMENT (see ADVERSE REACTIONS section). Renal impairment is most likely to become clinically evident during the second week of induction therapy, but may occur at any time during foscarnet sodium injection treatment. Renal function should be monitored carefully during both induction and maintenance therapy (see

No black box warning on record for Foscarnet Sodium

Other warnings & precautions

WARNINGS Renal Impairment THE MAJOR TOXICITY OF FOSCARNET SODIUM INJECTION IS RENAL IMPAIRMENT (see ADVERSE REACTIONS section). Renal impairment is most likely to become clinically evident during the second week of induction therapy, but may occur at any time during foscarnet sodium injection treatment. Renal function should be monitored carefully during both induction and maintenance therapy (see

Foscarnet Sodium Black Box Warning

No black box warning on record for Foscarnet Sodium

Other warnings & precautions

Foscarnet Sodium Black Box Warning

No black box warning on record for Foscarnet Sodium

Other warnings & precautions